Two to three weeks after treatment, the previously paralyzed mice began to walk. Credit: Lehrstuhl für Zellphysiologie
To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again. The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the Journal Nature Communications from 15 January 2021.
When the communication breaks down
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.
Designer protein stimulates regeneration
In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.
Applied in one area, effective in several areas
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements. They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously. “This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Rocket Pharmaceuticals' Promising Path In Gene Therapy
Rocket Pharmaceuticals' stock surged 76% following positive Phase 2 trial results for RP-A501. Read why RCKT is recommended a buy, for its unique market position.
- Positive Outlook for uniQure Backed by Strong Gene Therapy Pipeline and Strategic Advancements
H.C. Wainwright analyst Patrick Trucchio has maintained their bullish stance on QURE stock, giving a Buy rating on February 28. Patrick ...
- Optimistic Outlook for RegenXBio’s Gene Therapy Pipeline and Regulatory Prospects Spurs Buy Rating
Robert W. Baird analyst Brian Skorney maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 27 and set a price target ...
- Accelerating Progress in Cell and Gene Therapy
The remarkable advancements in cell and gene therapy (CGT) have ushered in a new era of medical possibilities, with the recent FDA approval of the first CRISPR therapy for sickle cell gene editing ...
- Novel Gene Editing Tool Improves Immune Cell Activity
Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in gene editing. The gene editing techn | Immunology ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”gene therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
My name is Ludy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics fourth-quarter and full-year 2023 financial results ...
- Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript February 28, 2024 Xencor, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good ...
- Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –– ARCALYST 2024 net ...
- Researchers reveal novel biochemical mechanism of cytokine-induced cell death
A physiological cytokine combination (TNF+IFNγ) has been identified that induces cell death in several cell lines in vitro. However, because TNF and IFNγ are multi-effector cytokines ...
- β chain signaling cytokines: Bioreagents to support research
The recurrent β chain signaling cytokines — granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3 and IL-5 — can control the growth, activities and differentiation of eosinophils ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”designer cytokine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]